Multi-national health care organization Centene Corporation (Centene) recently announced it will be funding up to $100 million in Alzheimer’s research at Washington University School of Medicine. In addition to Alzheimer’s, some of the funding will also help pay for research into breast cancer, diabetes, and obesity, as well.
As part of the agreement, Centene’s funds will be distributed over a 10 year period to the university’s Personalized Medicine Initiative. Any innovation emerging from the initiative will be jointly commercialized through both the Washington University School of Medicine and Centene.
Centene Corporation, a Fortune 100 company, is a diversified, multi-national health care enterprise that provides a portfolio of services to government sponsored and commercial health care programs, focusing on under-insured and uninsured individuals. The corporation provides health plans through Medicaid, Medicare and the Health Insurance Marketplace, and other Health Solutions through specialty service companies.
This was reported by Fierce Healthcare on April 9, 2019.
Contact Information: Centene Corporation, Centene Plaza 7700 Forsyth Boulevard, St. Louis, Missouri 63105; (314) 725-4477; Website: www.centene.com
Contact Information: Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, Missouri 63110; (314) 286-0100; Website: www.medicine.wustl.edu